Palliative and end-of-life care in Parkinson’s disease : French patients’ perceptions and knowledge
Objective: (1) Assess patients' perceptions and knowledge of palliative and end-of-life care in PD; (2) evaluate (i) whether patients discuss these topics with healthcare professionals and/or…A Prospective, Multicenter, Single-Arm Feasibility Study Examining ECAP-Controlled, Closed-Loop Spinal Cord Stimulation for Parkinson’s Disease (eCAP-PD): Technical and Design Considerations
Objective: Conduct a prospective feasibility study to determine the effects of ECAP-controlled closed-loop spinal cord stimulation (SCS) on motor symptoms in Parkinson’s disease (PD) patients.…Efficacy of Opicapone and Levodopa with Different Levodopa Daily Doses in Parkinson’s Disease Patients with Early Motor Fluctuations: Findings from the Korean ADOPTION Study
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus an additional levodopa (L-DOPA) dose of 100 mg in patients with Parkinson’s disease (PD)…Assessing a Video Based Approach at Measuring Parkinson’s Disease Severity – A Validation Study
Objective: To validate the Parkinson’s remote interactive monitoring system’s assessment of Parkinson’s disease compared to a clinical assessment completed by a movement disorder specialist. Background:…Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease
Objective: To evaluate the proportion of people with dopaminergic deficit and positive alpha-synuclein seed amplification assay (aSyn SAA) among a remotely identified group of hyposmic…Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)
Objective: To compare the safety and tolerability of once-daily opicapone (OPC) 50mg as add-on to stable levodopa/dopa decarboxylase inhibitor (L-DOPA/DDCI) therapy in patients from early…Five-Year Changes in MDS-UPDRS-III after Light Treatment (Photobiomodulation)
Objective: To determine the effectiveness of photobiomodulation (light therapy) on MDS-UPDRS-III scores over a five-year period Background: As a progressive neurodegenerative disease, worsening of motor…Slow-SPEED-NL: study protocol for a remote trial of exercise for Parkinson’s disease prevention
Objective: To determine the feasibility and preliminary efficacy of a remote exercise intervention in prodromal Parkinson’s disease (PD). Background: Disease-slowing interventions have been ineffective in…Exidavnemab offers opportunities as a potential disease modifying therapy in several synucleinopathies
Objective: Immunotherapy against α-synuclein is a promising novel treatment strategy for Parkinson's disease and related α-synucleinopathies. We have developed exidavnemab (BAN0805), a monoclonal antibody with…Safety and Efficacy of Sublingual Apomorphine in Parkinson’s Patients with or without Concomitant Dopamine Agonists Use
Objective: This post-hoc analysis of Study CTH-301 aimed to assess the safety and efficacy of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease with…
- « Previous Page
- 1
- …
- 251
- 252
- 253
- 254
- 255
- …
- 553
- Next Page »